Compare NEOG & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | IMTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1989 | N/A |
| Metric | NEOG | IMTX |
|---|---|---|
| Price | $6.86 | $10.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.83 | ★ $19.25 |
| AVG Volume (30 Days) | ★ 4.2M | 590.7K |
| Earning Date | 01-09-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $886,886,000.00 | $99,445,031.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.80 | $24.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.87 | $3.30 |
| 52 Week High | $13.41 | $12.41 |
| Indicator | NEOG | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 48.62 |
| Support Level | $5.82 | $9.86 |
| Resistance Level | $7.09 | $12.41 |
| Average True Range (ATR) | 0.27 | 0.71 |
| MACD | 0.11 | -0.10 |
| Stochastic Oscillator | 81.64 | 9.40 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.